CSL names veteran executive Gordon Naylor interim CEO as Paul McKenzie retires

The latest update is out from CSL ( (AU:CSL) ).

CSL has announced the retirement of Chief Executive Officer and Managing Director Paul McKenzie, with long‑time company executive and current non‑executive director Gordon Naylor appointed as interim CEO and MD effective 11 February. The leadership change follows McKenzie’s seven years with CSL, including three as CEO during which he steered the group through COVID‑19 disruptions, expanded plasma collection, launched new therapies such as HEMGENIX for haemophilia B and ANDEMBRY for hereditary angioedema, and advanced large‑scale operational transformation initiatives.

Chair Brian McNamee highlighted Naylor’s 33‑year history in senior roles at CSL, including as CFO and President of Seqirus, where he helped build the company’s global plasma and vaccine footprint and led a turnaround of the influenza business. The Board has given Naylor full authority to lead while it conducts a search for a permanent chief, signalling a focus on continuity in executing CSL’s strategic transformation, sustaining R&D investment and delivering growth for patients, public health systems and shareholders.

The most recent analyst rating on (AU:CSL) stock is a Hold with a A$198.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.

More about CSL

CSL Limited is a global biopharmaceutical company focused on plasma-derived therapies, vaccines and specialty medicines that treat serious and rare diseases. The company operates extensive plasma collection and manufacturing networks and has built leading positions in plasma therapies and influenza vaccines through businesses such as CSL Behring, CSL Plasma and Seqirus.

Average Trading Volume: 916,993

Technical Sentiment Signal: Sell

Current Market Cap: A$87.57B

For an in-depth examination of CSL stock, go to TipRanks’ Overview page.